BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 30391462)

  • 1. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma.
    Kaishang Z; Xue P; Shaozhong Z; Yingying F; Yan Z; Chanjun S; Zhenzhen L; Xiangnan L
    Life Sci; 2018 Dec; 215():159-169. PubMed ID: 30391462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma.
    Su X; Wan Y; Xie L; Lin X; Zhao H; Ju X; Fang A
    Med Sci Monit; 2019 Sep; 25():6691-6701. PubMed ID: 31489957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
    Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
    Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
    Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
    Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
    Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
    Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    Chen D; Luo L; Liang C
    PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of TWF1 promotes lung adenocarcinoma progression and is associated with poor prognosis in cancer patients through the MMP1 signaling pathway.
    Zhai K; Jiang N; Wen JF; Zhang X; Liu T; Long KJ; Ke XX; Xu G; Chen C
    J Thorac Dis; 2023 May; 15(5):2644-2658. PubMed ID: 37324107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.
    Chen J; Chen H; Yang H; Dai H
    Biomed Pharmacother; 2018 Apr; 100():233-239. PubMed ID: 29432994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
    Liu X; Chen L; Zhang T
    Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
    Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
    Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA VPS9D1-AS1 overexpression predicts a poor prognosis in non-small cell lung cancer.
    Tan J; Yang L
    Biomed Pharmacother; 2018 Oct; 106():1600-1606. PubMed ID: 30119235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis.
    Gao Z; Shi R; Yuan K; Wang Y
    Tumour Biol; 2016 Nov; 37(11):14979-14987. PubMed ID: 27655285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.